9 completed, 5 terminated, 5 unknown, 1 recruiting. 20 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 9, Terminated 5, Unknown 5, Recruiting 1 |
| Phase 2 | 5 | Completed 4, Recruiting 1 |
Follow Amantadine: new trials by email Literature Review of Amantadine trials Research Report on Amantadine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU Cerebrolysin, amantadine sulfate - Traumatic Brain Injury | Phase 3 | Completed | Ain Shams University | 150 | 2023-09-01 | 2025-11-19 |
| Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis Transcranial Magnetic Stimulation, Amantadine Hydrochloride 100 mg (milligrams) Oral Capsule - Multiple Sclerosis, Fatigue | Phase 3 | Unknown | Hospital San Carlos, Madrid | 144 | 2022-11-28 | 2023-12-11 |
| Amantadine for COVID-19 Amantadine, Lactose monohydrate - Covid19 | Phase 3 | Unknown | Copenhagen University Hospital, Hvidovre | 226 | 2021-06-01 | 2021-10-06 |
| Efficacy of Amantadine Treatment in COVID-19 Patients Amantadine - Patients With Moderate or Severe COVID-19 | Phase 3 | Terminated | Noblewell | 193 | 2021-03-30 | 2022-09-30 |
| The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms Amantadine Hydrochloride, Placebo - COVID-19, SARS-CoV-2 | Phase 3 | Unknown | Independent Public Clinical Hospital No. 4 in Lublin | 200 | 2021-03-15 | 2021-08-13 |
| Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial Memantine Hydrochloride Oral Solution, Trazodone Hydrochloride oral solution, Placebo oral solution - Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Recruiting | University of Edinburgh | 1150 | 2020-02-27 | 2026-03-04 |
| Treatment of Fatigue With Methylphenidate, Modafinil and Amantadine in Multiple Sclerosis Amantadine, Modafinil, Methylphenidate - Fatigue in Multiple Sclerosis | Phase 3 | Completed | Johns Hopkins University | 141 | 2017-10-04 | 2020-10-20 |
| Oral Amantadine Versus Gabapentin to Attenuate the Response to Laryngoscopy and Tracheal Intubation oral amantadine sulfate, oral gabapentin, Placebo Oral Tablet - Effect of Laryngoscopy and Tracheal Intubation | Phase 2 / Phase 3 | Completed | Ghada Mohammed AboelFadl | 90 | 2017-06-15 | 2018-09-25 |
| Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID. 240mg Amantadine HCl ER tablets, Placebo tablets, 320mg Amantadine HCl ER tablets - Parkinson's Disease, Levodopa Induced Dyskinesias (LID) | Phase 3 | Terminated | Adamas Pharmaceuticals, Inc. | 87 | 2014-08-18 | 2022-02-16 |
| Efficacy and Safety of Amantadine Hydrogen Chloride (HCl) ER Tablets in Parkinson's Disease Subjects With LID amantadine HCl ER, Placebo - Parkinson's Disease, Levodopa Induced Dyskinesia (LID) | Phase 3 | Terminated | Adamas Pharmaceuticals, Inc. | 135 | 2014-07-30 | 2022-02-16 |
| Efficacy Study of Amantadine to Treat Gait Dysfunction and Freezing in Parkinson's Disease Amantadine, Placebo - Parkinson's Disease | Phase 3 | Terminated | Northwestern University | 3 | 2011-06-01 | 2019-11-13 |
| Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia Amantadine, Placebo - Schizophrenia | Phase 3 | Unknown | Hospital de Clinicas de Porto Alegre | 40 | 2010-05-01 | 2011-02-16 |
| Action of Amantadine on Post-Stroke Aphasic Patients Amantadin, Placebo - Cerebral Infarction | Phase 2 / Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 50 | 2009-03-01 | 2014-04-21 |
| Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine olanzapine, amantadine, metformin - Schizophrenia, Schizoaffective Disorders | Phase 3 | Completed | Eli Lilly and Company | 199 | 2006-11-01 | 2009-10-06 |
| Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy Peginterferon alfa-2a, Ribavirin, Amantadine - Hepatitis C, Chronic, Relapse | Phase 3 | Unknown | University of Hamburg-Eppendorf | 300 | 2005-11-01 | 2007-03-09 |
| Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI) Amantadine Hydrochloride, Placebo - Traumatic Brain Injury | Phase 2 / Phase 3 | Completed | JFK Medical Center | 184 | 2003-02-01 | 2012-09-24 |
| Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine for the Treatment of Hepatitis C Infected Patients Peginterferon alfa-2a, ribavirin, amantadine - HCV Infection, Hepatitis C, Chronic | Phase 3 | Completed | University Hospital, Bordeaux | 131 | 2001-11-01 | 2007-06-13 |
| Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders peg-interferon alfa-2b, ribavirin, amantadine - Hepatitis C, Chronic | Phase 3 | Terminated | French National Agency for Research on AIDS and Viral Hepatitis | 405 | 2000-10-01 | 2005-07-29 |
| Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients Amantadine - Chronic Hepatitis C | Phase 3 | Completed | UMC Utrecht | 390 | 2000-02-01 | 2005-09-05 |
| Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Non-responders interferon alpha-2b, ribavirin, interferon-gamma,, interferon alpha-2b, ribavirin, amantadine - Hepatitis C, Genotype 3 | Phase 2 / Phase 3 | Completed | Aga Khan University | 40 | 2010-10-27 |
Hepatitis C, Chronic (4) · COVID-19 (3) · Parkinson Disease (3) · Brain Injuries, Traumatic (2) · Dyskinesias (2) · Hepatitis C (2) · Parkinsonian Disorders (2) · Schizophrenia (2) · Amyotrophic Lateral Sclerosis (1) · Cerebral Infarction (1) · Consciousness Disorders (1) · Fatigue (1) · Multiple Sclerosis (1) · Psychotic Disorders (1) · Recurrence (1)
Adamas Pharmaceuticals, Inc. (2) · Aga Khan University (1) · Ain Shams University (1) · Centre Hospitalier Universitaire de Nice (1) · Copenhagen University Hospital, Hvidovre (1) · Eli Lilly and Company (1) · French National Agency for Research on AIDS and Viral Hepatitis (1) · Ghada Mohammed AboelFadl (1) · Hospital San Carlos, Madrid (1) · Hospital de Clinicas de Porto Alegre (1) · Independent Public Clinical Hospital No. 4 in Lublin (1) · JFK Medical Center (1) · Johns Hopkins University (1) · Noblewell (1) · Northwestern University (1)
United States (6) · France (5) · Germany (4) · Spain (3) · Brazil (2) · Canada (2) · Denmark (2) · Egypt (2) · Poland (2) · Israel (1) · Mexico (1) · Netherlands (1) · Pakistan (1) · Puerto Rico (1) · Russia (1)
Angela Dentiste, MBA (2) · Abualauon Elpiplaoy, MD (1) · Adam Barczyk, Prof. (1) · Bardia Nourbakhsh, MD (1) · Christian Trepo, MD (1) · Clarissa S Gama, MD, PhD (1) · John Whyte, MD, Ph.D. (1) · Jorge Matias-Guiu Guia, MD PhD (1) · Joseph T. Giacino, Ph.D. (1)
PMID 20729740, PMID 20840778, PMID 21672497, PMID 22375973, PMID 22755276, PMID 29113955, PMID 33242419, PMID 35390511, PMID 35798516, PMID 36647114, PMID 36725099, PMID 36931576, PMID 38176857, PMID 39307154